GlassScriptPhysician profile
Robert M Lancaster
NPI 1811409006
$6,172.66
in general payments reported to CMS, 2019-2025
40 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $735 · 2022: $926 · 2023: $1,427 · 2024: $1,373 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,511.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $875.02 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $835.22 | 2021-2025 | |
| Abbvie INC. | $833.84 | 2021-2025 | |
| Amgen INC. | $496.68 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $460.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.77 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $260.72 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $255.71 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.60 | 2021-2024 | Trulance, Xifaxan |
| Janssen Pharmaceuticals, INC | $169.05 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $165.19 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $160.92 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $112.10 | 2021 | |
| Phathom Pharmaceuticals, INC. | $89.57 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $83.46 | 2021-2024 | Gardasil 9, Belsomra, Gardasil |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.